Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EC-MPS in de Novo Kidney Transplant Recipients
NCT00238953Phase 4Completed
- Sponsor
- Novartis
- Start
- Feb 2005
- Primary completion
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mycophenolate sodium in kidney transplant rejection, sponsored by Novartis. Primary endpoints: Patient Survival at 6 months, Graft Survival at 6 months and 3 more. Started Feb 2005; status: completed.
02
Drugs
mycophenolate sodium
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00238953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00238953.